News from biovaxys technology corp. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 19, 2022, 23:49 ET BioVaxys gibt Standort und Hauptprüfer für die erste klinische Studie seines Impfstoffs gegen Eierstockkrebs bekannt und schließt eine zweite Vereinbarung zur Bereitstellung von Tumorzellen ab

BioVaxys Technology Corp. (CSE: BIOV; FRA: 5LB; OTCQB: BVAXF)(„BioVaxys" oder „da Unternehmen") hat heute bekannt gegeben, dass eine Übereinkunft mit ...

May 19, 2022, 02:08 ET Le premier site clinique et les premiers chercheurs principaux de l'essai du vaccin contre le cancer de l'ovaire sont confirmés par BioVaxys, qui conclut un deuxième accord de fourniture de cellules tumorales

BioVaxys Technology Corp. (CSE: BIOV ; FRA: 5LB ; OTCQB: BVAXF) (« BioVaxys » ou la « Société »), a annoncé aujourd'hui que les Hospices Civils de...

May 18, 2022, 08:00 ET BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement

BioVaxys Technology Corp. (CSE: BIOV; FRA: 5LB; OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that Hospices Civils de Lyon, France ("HCL") ...

May 18, 2022, 08:00 ET BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement

BioVaxys Technology Corp. (CSE: BIOV; FRA: 5LB; OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that Hospices Civils de Lyon, France ("HCL") ...

May 02, 2022, 08:00 ET Impfstoff gegen Gebärmutterhalskrebs

BioVaxys Technology Corp. (CSE: BIOV), (FRA:5LB), (OTCQB:BVAXF) ("BioVaxys" oder „Unternehmen"), gab heute bekannt, dass das Unternehmen die...

May 02, 2022, 08:00 ET International Patent Application Filed for Cervical Cancer Vaccine

BioVaxys Technology Corp. (CSE: BIOV), (FRA:5LB), (OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has continued to expand the patent ...

May 02, 2022, 08:00 ET International Patent Application Filed for Cervical Cancer Vaccine

BioVaxys Technology Corp. (CSE: BIOV), (FRA:5LB), (OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has continued to expand the patent ...

Apr 29, 2022, 08:32 ET BIOVAXYS ANNOUNCES APPOINTMENT TO BOARD OF DIRECTORS

BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that Mr. Anthony Dutton has been...

Apr 25, 2022, 09:13 ET BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction

BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has entered into an agreement with the ...

Mar 31, 2022, 23:09 ET BioVaxys erweitert Krebsimpfstoff-Plattform

BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) („BioVaxys" oder „Unternehmen") gab heute die Erweiterung seiner...

Mar 31, 2022, 23:05 ET BioVaxys élargit sa plateforme de vaccination contre le cancer

BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) (« BioVaxys » ou la « Société ») a annoncé aujourd'hui l'expansion de sa plateforme ...

Mar 30, 2022, 11:23 ET BioVaxys amplía su plataforma de vacuna contra el cáncer

BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" o "la compañía"), anunció hoy la expansión de su plataforma de vacunas...

Mar 30, 2022, 03:24 ET BioVaxys Expands Cancer Vaccine Platform

BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today the expansion of its cancer vaccine...

Mar 19, 2022, 08:46 ET BioVaxys annonce la bioproduction du BVX-1021 dans le cadre de son programme pan-sarbecovirus, en collaboration avec l'Université d'État de l'Ohio

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (« BioVaxys » ou la « Société »), a annoncé aujourd'hui la conclusion avec...

Mar 17, 2022, 19:25 ET BioVaxys kündigt Bioproduktion von BVX-1021 für sein Pan-Sarbecovirus-Programm in Zusammenarbeit mit der Ohio State University an

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) („BioVaxys" oder das „Unternehmen"), hat heute bekannt gegeben, eine Vereinbarung mit ...

Mar 17, 2022, 11:49 ET BioVaxys anuncia la bioproducción de BVX-1021 para su programa pan-sarbecovirus

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" o la "Compañía"), anunció hoy que ha llegado a un acuerdo con...

Mar 17, 2022, 08:00 ET BioVaxys Announces Bioproduction of BVX-1021 for its Pan-Sarbecovirus Program in Collaboration with The Ohio State University

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has entered into an agreement with ...

Mar 17, 2022, 08:00 ET BioVaxys Announces Bioproduction of BVX-1021 for its Pan-Sarbecovirus Program in Collaboration with The Ohio State University

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has entered into an agreement with ...

Feb 28, 2022, 08:00 ET BioVaxys Closes Final Tranche of Non-brokered Private Placement

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has closed the second...

Feb 18, 2022, 00:04 ET BIOVAXYS gibt vollständige Hemmung der ACE-2-Bindungsaktivität des hapten-modifizierten SARS-CoV-2-Proteins bekannt

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAX) („BioVaxys" oder „Unternehmen") hat heute bekannt gegeben, dass Studien zu BVX-0320,...

Feb 16, 2022, 08:00 ET BIOVAXYS ANNOUNCES complete inhibition of ACE-2 binding activity of hapten-modified SARS-CoV-2 protein

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAX) ("BioVaxys" or "Company") announced today that studies on BVX-0320, its haptenized...

Feb 16, 2022, 08:00 ET BIOVAXYS ANNOUNCES complete inhibition of ACE-2 binding activity of hapten-modified SARS-CoV-2 protein

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAX) ("BioVaxys" or "Company") announced today that studies on BVX-0320, its haptenized...

Feb 10, 2022, 02:37 ET BIOVAXYS CLOSES FIRST TRANCHE OF NON-BROKERED PRIVATE PLACEMENT

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has closed the first...

Feb 08, 2022, 01:02 ET BIOVAXYS ANNOUNCES NON-BROKERED PRIVATE PLACEMENT

BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce a non-brokered private...

Dec 09, 2021, 05:13 ET Biovaxys kündigt bedeutende Forschungskooperation mit der Ohio State University zur Entwicklung eines breit reaktiven Pan-Sarbecovirus-Impfstoffs an

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) („BioVaxys" oder das „Unternehmen"), ein Immuntherapie-Unternehmen für klinische...